These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38447437)

  • 1. Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS).
    Bashir B; Kwok S; Wierzbicki AS; Jones A; Dawson C; Downie P; Jenkinson F; Delaney H; Mansfield M; Datta D; Teoh Y; Hamilton P; Forrester N; O'Sullivan D; Ferdousi M; Durrington PN; AbdelRazik A; Gallo A; Moulin P; Soran H
    Atherosclerosis; 2024 Apr; 391():117476. PubMed ID: 38447437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".
    Moulin P; Dufour R; Averna M; Arca M; Cefalù AB; Noto D; D'Erasmo L; Di Costanzo A; Marçais C; Alvarez-Sala Walther LA; Banach M; Borén J; Cramb R; Gouni-Berthold I; Hughes E; Johnson C; Pintó X; Reiner Ž; van Lennep JR; Soran H; Stefanutti C; Stroes E; Bruckert E
    Atherosclerosis; 2018 Aug; 275():265-272. PubMed ID: 29980054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score.
    Moulin P; Dufour R; Averna M; Arca M; Cefalù AB; Noto D; D'Erasmo L; Di Costanzo A; Marçais C; Walther LAA; Banach M; Borén J; Cramb R; Gouni-Berthold I; Hughes E; Johnson C; Pintó X; Reiner Ž; van Lennep JR; Soran H; Stefanutti C; Stroes E; Bruckert E
    Data Brief; 2018 Dec; 21():1334-1336. PubMed ID: 30456254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome-Causes, Clinical Presentation, and Therapeutic Options.
    Bashir B; Ho JH; Downie P; Hamilton P; Ferns G; Datta D; Cegla J; Wierzbicki AS; Dawson C; Jenkinson F; Delaney H; Mansfield M; Teoh Y; Miedzybrodzka Z; Haso H; Durrington PN; Soran H
    Metabolites; 2023 Apr; 13(5):. PubMed ID: 37233662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of lipoprotein lipase activity measurement in the diagnosis of familial chylomicronemia syndrome.
    Rioja J; Ariza MJ; Benítez-Toledo MJ; Espíldora-Hernández J; Coca-Prieto I; Arrobas-Velilla T; Camacho A; Olivecrona G; Sánchez-Chaparro MÁ; Valdivielso P
    J Clin Lipidol; 2023; 17(2):272-280. PubMed ID: 36813655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome.
    Paquette M; Amyot J; Fantino M; Baass A; Bernard S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3473-e3482. PubMed ID: 34019660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia.
    Paquette M; Bernard S; Hegele RA; Baass A
    Atherosclerosis; 2019 Apr; 283():137-142. PubMed ID: 30655019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chylomicronemia.
    Navarro Hermoso A; Valdivielso P
    Clin Investig Arterioscler; 2021 May; 33 Suppl 2():75-79. PubMed ID: 34006359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS).
    Jones A; Peers K; Wierzbicki AS; Ramachandran R; Mansfield M; Dawson C; Ochoa-Ferraro A; Soran H; Jenkinson F; McDowell I; Downie P; Hamilton P; Jones RD
    Atherosclerosis; 2023 Jun; 375():67-74. PubMed ID: 37253281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 10-Year Comparative Follow-up of Familial versus Multifactorial Chylomicronemia Syndromes.
    Belhassen M; Van Ganse E; Nolin M; Bérard M; Bada H; Bruckert E; Krempf M; Rebours V; Valero R; Moulin P
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1332-e1342. PubMed ID: 33221907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lomitapide in familial chylomicronaemia syndrome.
    Cefalù AB; D'Erasmo L; Iannuzzo G; Noto D; Giammanco A; Montali A; Zambon A; Forte F; Suppressa P; Giannini S; Barbagallo CM; Ganci A; Nardi E; Vernuccio F; Caldarella R; Ciaccio M; Arca M; Averna M
    Atherosclerosis; 2022 Oct; 359():13-19. PubMed ID: 36152419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.
    Baass A; Paquette M; Bernard S; Hegele RA
    J Intern Med; 2020 Apr; 287(4):340-348. PubMed ID: 31840878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyses of familial chylomicronemia syndrome in Pereira, Colombia 2010-2020: a cross-sectional study.
    Rodriguez FH; Estrada JM; Quintero HMA; Nogueira JP; Porras-Hurtado GL
    Lipids Health Dis; 2023 Mar; 22(1):43. PubMed ID: 36978188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment.
    Gallo A; Béliard S; D'Erasmo L; Bruckert E
    Curr Atheroscler Rep; 2020 Aug; 22(11):63. PubMed ID: 32852651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the chylomicron-TG to VLDL-TG ratio for type I hyperlipoproteinemia diagnostic.
    Rioja J; Ariza MJ; García-Casares N; Coca-Prieto I; Arrobas T; Muñiz-Grijalvo O; Mangas A; Ibarretxe D; Sánchez-Chaparro MÁ; Valdivielso P
    Eur J Clin Invest; 2020 Dec; 50(12):e13345. PubMed ID: 32649781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes.
    D'Erasmo L; Di Costanzo A; Cassandra F; Minicocci I; Polito L; Montali A; Ceci F; Arca M
    Arterioscler Thromb Vasc Biol; 2019 Dec; 39(12):2531-2541. PubMed ID: 31619059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characterization and mutation spectrum of patients with hypertriglyceridemia in a German outpatient clinic.
    Bardey F; Rieck L; Spira D; März W; Binner P; Schwab S; Kleber ME; Danyel M; Barkowski R; Bobbert T; Spranger J; Steinhagen-Thiessen E; Demuth I; Kassner U
    J Lipid Res; 2024 Jul; ():100589. PubMed ID: 38969064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Alcoholic Fatty Liver in Patients with Chylomicronemia.
    Maltais M; Brisson D; Gaudet D
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33572376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic algorithm for familial chylomicronemia syndrome.
    Stroes E; Moulin P; Parhofer KG; Rebours V; Löhr JM; Averna M
    Atheroscler Suppl; 2017 Jan; 23():1-7. PubMed ID: 27998715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chylomicronemia syndrome: Familial or not?
    Warden BA; Minnier J; Duell PB; Fazio S; Shapiro MD
    J Clin Lipidol; 2020; 14(2):201-206. PubMed ID: 32107181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.